Atea Pharmaceuticals, Inc.
NASDAQ:AVIRBiotechnology
-$0.04 today
- Market cap
- $320.41M
- Beta
- 0.32
- P/E (TTM)
- -2.0
- EPS (TTM)
- -$2.14
Volume 0.34M
Average 0.34M
AVIR Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Atea Pharmaceuticals, Inc.NASDAQ: AVIR
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation declines year over year
Q1 FY2026 stock-based compensation of $3.73M fell 46.4% year over year, ahead of the -62.1% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 18.7% from the prior quarter. Over 3 fiscal years it compounded at -23.7% a year.
Context
- Stock-based compensation increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -46.4% holds above the trailing-twelve-month pace of -62.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 20.72M USD
- Year-over-year change
- -60.0%
- 4-year CAGR
- -15.0%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 20.72M | -60.0% |
| FY2024 | 2024-12-31 | 51.77M | +4.7% |
| FY2023 | 2023-12-31 | 49.43M | +5.8% |
| FY2022 | 2022-12-31 | 46.72M | +17.9% |
| FY2021 | 2021-12-31 | 39.62M | — |
Stock-Based Compensation vs competitors
How AVIR compares with its peers on the latest reported figures
- AVIR's LTM Mar 2026 stock-based compensation of $17.5M is the 3rd largest of the 5 companies compared; the peer median is $17.1M.
- Its year-over-year change of -62.1% is the lowest of 5, against a peer median of +40.7%.
- Over three fiscal years its annual growth of -23.7% compares with a peer median of -11.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $35.01M | +17.1% | -21.7% | 53.5% | |
| LTM Mar 2026 | $18.43M | +74.9% | -1.1% | 9.6% | |
| LTM Mar 2026 | $17.5M | -62.1% | -23.7% | — | |
| LTM Mar 2026 | $15.77M | -32.9% | -11.7% | 22.8% | |
| LTM Mar 2026 | $5.08M | +64.3% | -10.8% | 7.1% | |
| Peer median (excluding AVIR) | $17.1M | +40.7% | -11.3% | 16.2% | |
Competitors are the stored peer set for AVIR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 121.19M | (115.91M) | (135.96M) | (168.39M) | (158.35M) |
| Depreciation & Amortization | 29K | 260K | 416K | 416K | 416K |
| Deferred Income Tax | (29.39M) | 0 | (48.56M) | 0 | (6.36M) |
| Stock-Based Compensation | 39.62M | 46.72M | 49.43M | 51.77M | 20.72M |
| Change in Working Capital | (247.85M) | (46.59M) | 16.16M | (7.48M) | 16.48M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 10.29M | (1.98M) | 1.7M | 206K | 8.49M |
| Other Working Capital | (258.13M) | (44.6M) | 14.46M | (7.68M) | 8M |
| Other Non-Cash Items | 29.39M | (5.47M) | 33.11M | (11.82M) | (4.94M) |
| Operating Cash Flow | (87.01M) | (120.98M) | (85.4M) | (135.5M) | (132.03M) |
| Capital Expenditures | (4K) | (1.94M) | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 453.47K | 0 | 0 | 0 |
| Purchases of Investments | 0 | (545.35M) | (562.36M) | (461.18M) | (281.94M) |
| Sales of Investments | 0 | 91.89M | 602.67M | 517.28M | 470.73M |
| Other Investing Activities | 0 | (453.47K) | 0 | 0 | 0 |
| Investing Cash Flow | (4K) | (455.41M) | 40.3M | 56.11M | 188.79M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 1.47M | 230K | 257K | 267K | 259K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (25.52M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 140K | 0 | 0 | (485K) |
| Financing Cash Flow | 1.47M | 370K | 257K | 267K | (25.75M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (85.54M) | (576.02M) | (44.84M) | (79.13M) | 31.02M |
| Free Cash Flow | (87.01M) | (122.93M) | (85.4M) | (135.5M) | (132.03M) |
Atea Pharmaceuticals, Inc.
NASDAQ:AVIR
Intrinsic Alpha fair value
Locked
Current Price
$3.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.